SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as community members speculate on potential rallies and the impact of upcoming events. Bullish sentiment is fueled by discussions of market structure and potential for new partnerships. Some traders are debating optimal entry points and whether to accumulate more coins.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is trending as the community speculates on its potential for significant gains, with many highlighting strong buying activity and bullish sentiment. Conversations are also focused on the project's legitimacy, with some users drawing comparisons to a previous project called $PUPU.X from the same team and warning of potential risks.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members weighing in on its long-term potential and sustainability, with some expressing concerns about its burn rate and overall design. Discussions also revolve around potential AI integration and comparisons to other meme coins, including newer Solana-based tokens. The conversation highlights the volatile nature of meme coins and the importance of community sentiment.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X, a Solana-based meme token, is gaining attention as the community rallies around its 'UpTober' theme and close-knit holder base. Active discussions revolve around its unique 'dad joke' meta and comparisons to other dog-themed cryptos. Community members highlight its presence on the Jupiter Strict List as a positive signal.

Hang Feng Technology Innovation Co Ltd.

Hang Feng Technology Innovation Co Ltd

FOFO is trending due to its recent explosive price action and high volume, reminiscent of past high-momentum stocks. The community is discussing its potential as a "pump and dump", comparing it to other Chinese IPOs, and debating whether to chase the rally or wait for a pullback. Some are also highlighting its low float and the fear of missing out (FOMO) as potential drivers.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to recent case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, potentially reducing the need for invasive procedures; the community is discussing the stock's high trading volume and potential for significant growth, especially given its small float and focus on lung cancer diagnostics; some see it as a long-term investment while others are focused on swing trading opportunities.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential use by SWIFT for stablecoin payment tests, which is seen as a major validation of blockchain technology. Bullish sentiment is fueled by the possible implications for the Ethereum ecosystem, particularly regarding scalability and efficiency in financial operations. Some users are speculating about potential price increases and comparing Linea favorably to other cryptocurrencies.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending amid community excitement, with many touting it as the first ETF on Solana and anticipating significant gains. The community is actively encouraging others to join, emphasizing its strong core of investors and the potential for substantial returns during the upcoming meme season, while also mentioning its connection to UpDog.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending amidst discussions about its potential, with community members debating its long-term viability and whether it represents a worthwhile opportunity in the crypto space. Some users are focused on the upcoming KYC deadline and speculating on its impact, while others are sharing price predictions and expressing frustration over exchange listings. Bullish users encourage others to accumulate Pi, emphasizing its potential for future value and utility.

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is trending due to community discussion around its potential in the biotech sector, particularly regarding its clinical catalysts and high volume trading sessions. Community members are actively analyzing trading patterns, including end-of-day volume spikes, and speculating on news catalysts and possible institutional accumulation. Bullish sentiment remains, with some viewing the stock as undervalued and highlighting its strong cash position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

Equity

Peering Into ZyVersa Therapeutics's Recent Short Interest

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 646,000 shares...

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical...

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator  VAR 200 in Patients with Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration...

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled  Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Growth in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) was the target of a large growth in short interest in February. As of February 29th, there was short interest totalling 1,190,000...

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...

ZyVersa Therapeutics highlights data from publication on IC 100

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

ZyVersa Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

ZVSA
ZyVersa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest ZVSA News

ZVSA ZyVersa Therapeutics Inc